Kadcyla, a new breast cancer drug by Roche, was approved in Japan and, furthermore, recommended for approval in Europe and possibly headed for the United States next February, according to a Reuters report on Friday.
The drug is for patients with late-stage disease whose cancer cells contain increased portions of HER2 – a protein. Scientifically, Kadcyla functions by connecting Herceptin to DM1 – a drug developed by Immuno Gen – which, in turn, interrupts the grown of cancer cells. Immuno Gen is to receive a $5 million milestone payment from Roche when the approval of the drug as the drug is approved in Japan.
More medical news on Friday includes the EMA (European Medicines Agency) experts recommended medicine for prostate cancer on Friday, also. Algeta and Bayer’s drug called Xofigo is the prostate cancer drug that was previously approved in the United States.
Also, the EMA has recommended Ivokana, which is Johnson & Johnson’s diabetes mediation, Viteka which is Gilead’s HIV treatment, Relvar which is Glaxo Smith Kline’s lung drug, a premature ejaculation therapy from Plethora Solutions, and several other drugs that combat the flu, hemophilia, and schizophrenia.